<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999556</url>
  </required_header>
  <id_info>
    <org_study_id>LCI-HEM-SPEC-001</org_study_id>
    <secondary_id>00008179</secondary_id>
    <nct_id>NCT01999556</nct_id>
  </id_info>
  <brief_title>LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia</brief_title>
  <official_title>LCI-HEM-SPEC-001: Tissue Collection for Familial Acute Myelogenous Leukemia Genetic Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belinda Avalos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carolinas Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain high quality specimens for molecular studies for the
      identification and characterization of genetic mutations involved in the pathogenesis of
      familial myeloid malignancies. Specimens obtained will be de-identified, linked to basic
      clinical data, and sent to Washington University (Division of Oncology, St. Louis, MO) for
      molecular analyses. Some specimens sent to Washington University may also be used for quality
      control analyses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a specimen collection study for patients receiving standard of care treatment for
      AML. Specimens collected will be 1) bone marrow biopsy and aspiration, 2) peripheral blood,
      3) skin punch biopsy, and 4) oral rinse. Collection of these specimens will be at timepoints
      determined by the patient's standard of care and their physician Investigator.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with the mutation for acute myelogenous leukemia.</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leukemia, Myelogenous, Acute</condition>
  <arm_group>
    <arm_group_label>Patient</arm_group_label>
    <description>Specimen Collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relative</arm_group_label>
    <description>Specimen Collection</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients must have a diagnosis of acute myelogenous leukemia. Family members of patients
        with acute myelogenous leukemia may be enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients must have a diagnosis of acute myelogenous leukemia.

          -  Family members of patients with acute myelogenous leukemia may be enrolled.

          -  Informed consent must be provided by the patient or his/her legal guardian in accord
             with the practices of Levine Cancer Institute and Carolinas Healthcare System.

        Exclusion Criteria

          -  Known infection with Hepatitis B or C, HTLV, or HIV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Belinda Avalos, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolinas Healthcare System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mai Luong, BA</last_name>
    <phone>980-442-2341</phone>
    <email>Mai.Luong@carolinashealthcare.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Belinda Avalos, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>December 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Carolinas Healthcare System</investigator_affiliation>
    <investigator_full_name>Belinda Avalos</investigator_full_name>
    <investigator_title>Belinda Avalos</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

